Relmada Therapeutics (RLMD) Long-Term Debt Issuances (2017 - 2018)

Relmada Therapeutics (RLMD) reported Long-Term Debt Issuances of $26700.0 for Q1 2018, down 98.92% quarter-over-quarter from $2.5 million in Q4 2017.

Relmada Therapeutics (RLMD) Long-Term Debt Issuances (2017 - 2018) Analysis & Trends

Relmada Therapeutics (RLMD) has 2 years of Long-Term Debt Issuances data on file, last reported at $26700.0 in Q1 2018.

Long-Term Debt Issuances for Q1 2018 came in at $26700.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2018 was $6.5 million (changed N/A YoY), and the FY2018 annual result was $6.5 million, changed N/A from the prior year.
Long-Term Debt Issuances slipped to $26700.0 in Q1 2018 per RLMD's latest filing, from $2.5 million in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $4.0 million in Q3 2017 and troughed at $26700.0 in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	2.73 Mn
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	-
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Relmada Therapeutics	581.07 Mn	581.07 Mn	-	-

Download Data